Telomere length in Parkinson's disease: A meta-analysis

Experimental Gerontology

Volumn 75, Issue , 2016, Pages 53-55

  Forero, Diego A ^a   González Giraldo, Yeimy ^b   López Quintero, Catalina ^c   Castro Vega, Luis J ^d   Barreto, George E ^b,e   Perry, George ^f  

^a CENTRO DE INVESTIGACIONES   (Colombia)

^b PONTIFICIA UNIVERSIDAD JAVERIANA   (Colombia)

^c MICHIGAN STATE UNIVERSITY   (United States)

^d PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

^e UNIVERSIDAD AUTÓNOMA DE CHILE   (Chile)

^f The University of Texas at San Antonio   (United States)

Author keywords

Epigenomics; Meta analysis; Movement disorders; Parkinson's disease; Telomeres

Indexed keywords

GENOMIC DNA;

ARTICLE; ASIAN; BRAIN REGION; CHROMOSOMAL PARAMETERS; DISEASE ASSOCIATION; EPIGENETICS; EUROPEAN; HUMAN; PARKINSON DISEASE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TELOMERE LENGTH; CASE CONTROL STUDY; GENETICS; META ANALYSIS; PATHOLOGY; RISK FACTOR; TELOMERE; TELOMERE SHORTENING;

CASE-CONTROL STUDIES; HUMANS; PARKINSON DISEASE; RISK FACTORS; TELOMERE; TELOMERE SHORTENING;

EID: 84954570754     PISSN: 05315565     EISSN: 18736815     Source Type: Journal    
DOI: 10.1016/j.exger.2016.01.002     Document Type: Article

References (20)

1. Aviv A., Hunt S.C., Lin J., Cao X., Kimura M., Blackburn E. Impartial comparative analysis of measurement of leukocyte telomere length/DNA content by Southern blots and qPCR. Nucleic Acids Res. 2011, 39:e134.
2. Cawthon R.M. Telomere length measurement by a novel monochrome multiplex quantitative PCR method. Nucleic Acids Res. 2009, 37:e21.
3. Degerman S., Domellof M., Landfors M., Linder J., Lundin M., Haraldsson S., Elgh E., Roos G., Forsgren L. Long leukocyte telomere length at diagnosis is a risk factor for dementia progression in idiopathic parkinsonism. PLoS ONE 2014, 9.
4. Eerola J., Kananen L., Manninen K., Hellstrom O., Tienari P.J., Hovatta I. No evidence for shorter leukocyte telomere length in Parkinson's disease patients. J. Gerontol. A Biol. Sci. Med. Sci. 2010, 65:1181-1184.
5. Eitan E., Hutchison E.R., Mattson M.P. Telomere shortening in neurological disorders: an abundance of unanswered questions. Trends Neurosci. 2014, 37:256-263.
6. Elbers C.C., Garcia M.E., Kimura M., Cummings S.R., Nalls M.A., Newman A.B., Park V., Sanders J.L., Tranah G.J., Tishkoff S.A., Harris T.B., Aviv A. Comparison between Southern blots and qPCR analysis of leukocyte telomere length in the health ABC study. J. Gerontol. A Biol. Sci. Med. Sci. 2014, 69:527-531.
7. Forero D.A., Lopez-Leon S., Shin H.D., Park B.L., Kim D.J. Meta-analysis of six genes (BDNF, DRD1, DRD3, DRD4, GRIN2B and MAOA) involved in neuroplasticity and the risk for alcohol dependence. Drug Alcohol Depend. 2015, 149:259-263.
8. Guan J.Z., Maeda T., Sugano M., Oyama J., Higuchi Y., Suzuki T., Makino N. A percentage analysis of the telomere length in Parkinson's disease patients. J. Gerontol. A Biol. Sci. Med. Sci. 2008, 63:467-473.
9. Hudson G., Faini D., Stutt A., Eccles M., Robinson L., Burn D.J., Chinnery P.F. No evidence of substantia nigra telomere shortening in Parkinson's disease. Neurobiol. Aging 2011, 32(2107):e2103-e2105.
10. Lees A.J., Hardy J., Revesz T. Parkinson's disease. Lancet 2009, 373:2055-2066.
11. Lustig A.J. Potential risks in the paradigm of basic to translational research: a critical evaluation of qPCR telomere size techniques. J. Cancer Epidemiol. Treat. 2015, 1:28-37.
12. Maeda T., Guan J.Z., Koyanagi M., Higuchi Y., Makino N. Aging-associated alteration of telomere length and subtelomeric status in female patients with Parkinson's disease. J. Neurogenet. 2012, 26:245-251.
13. Moher D., Liberati A., Tetzlaff J., Altman D.G., Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009, 6.
14. Oeckl P., Scheffold A., Lechel A., Rudolph K.L., Ferger B. Substantial telomere shortening in the substantia nigra of telomerase-deficient mice does not increase susceptibility to MPTP-induced dopamine depletion. Neuroreport 2014, 25:335-339.
15. Schurks M., Buring J., Dushkes R., Gaziano J.M., Zee R.Y., Kurth T. Telomere length and Parkinson's disease in men: a nested case-control study. Eur. J. Neurol. 2014, 21:93-99.
16. Verstraeten A., Theuns J., Van Broeckhoven C. Progress in unraveling the genetic etiology of Parkinson disease in a genomic era. Trends Genet. 2015, 31:140-149.
17. von Elm E., Altman D.G., Egger M., Pocock S.J., Gotzsche P.C., Vandenbroucke J.P., Initiative S. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med. 2007, 4.
18. Wallace B.C., Schmid C.H., Lau J., Trikalinos T.A. Meta-analyst: software for meta-analysis of binary, continuous and diagnostic data. BMC Med. Res. Methodol. 2009, 9:80.
19. Wang H., Chen H., Gao X., McGrath M., Deer D., De Vivo I., Schwarzschild M.A., Ascherio A. Telomere length and risk of Parkinson's disease. Mov. Disord. 2008, 23:302-305.
20. Watfa G., Dragonas C., Brosche T., Dittrich R., Sieber C.C., Alecu C., Benetos A., Nzietchueng R. Study of telomere length and different markers of oxidative stress in patients with Parkinson's disease. J. Nutr. Health Aging 2011, 15:277-281.